Denise Curry, MD
Psychiatry · Saint Louis, MONPI 1891786406
Payments from drug & device makers
Across 73 payments — averaging $102.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$4K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$608
- Ironshore Pharmaceuticals Inc.$491
- Novo Nordisk$444
- E.r. Squibb & Sons, L.L.C.$367
- Johnson & Johnson$324
- plus $2K from 16 others
What the payments were for
- Consulting fees$2,75037%
- Travel & lodging$80011%
- Food & beverage$3,90952%
- Education$180%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 9 | $3,692 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 7 | $608 |
| Ironshore Pharmaceuticals Inc. | 6 | $491 |
| Novo Nordisk | 4 | $444 |
| E.r. Squibb & Sons, L.L.C. | 3 | $367 |
| Johnson & Johnson | 8 | $324 |
| Vanda Pharmaceuticals Inc. | 3 | $271 |
| Alkermes, Inc. | 4 | $247 |
| Otsuka America Pharmaceutical, Inc. | 10 | $230 |
| Jazz Pharmaceuticals Inc. | 1 | $155 |
| AbbVie | 4 | $141 |
| Lilly USA, LLC | 1 | $123 |
| TMS Neurohealth Centers Inc. | 1 | $98 |
| Neuronetics, Inc. | 1 | $90 |
| Teva Pharmaceuticals USA, Inc. | 1 | $33 |
| Sunovion Pharmaceuticals Inc. | 2 | $32 |
| Arbor Pharmaceuticals, Inc. | 2 | $30 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $28 |
| Almatica Pharma LLC | 1 | $24 |
| Indivior Inc. | 1 | $22 |
| Bausch Health US, LLC | 1 | $14 |
| Genentech USA, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,477 in reported general payments places this provider in the 85th percentile of 680 psychiatry providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 33 | $108,602 |
| CaplytaLumateperone Tosylate | 31 | $49,564 |
| Abilify MaintenaAripiprazole | 18 | $43,708 |
| LybalviOlanzapine/Samidorphan Malate | 29 | $43,105 |
| AristadaAripiprazole Lauroxil | 13 | $41,159 |
| UzedyRisperidone | 11 | $20,301 |
| FanaptIloperidone | 17 | $19,921 |
| BelsomraSuvorexant | 21 | $8,316 |
| Divalproex Sodium ErDivalproex Sodium | 69 | $2,703 |
| Vilazodone Hcl | 14 | $2,395 |
| Naltrexone Hcl | 50 | $2,019 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 47 | $1,890 |
| Lisdexamfetamine Dimesylate | 11 | $1,504 |
| Buspirone Hcl | 107 | $1,486 |
| Olanzapine | 76 | $1,470 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $324 | $108,60233 claims |
| Alkermes, Inc.Lybalvi, Aristada | $247 | $84,26442 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $608 | $49,56431 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $230 | $43,70818 claims |
| Teva Pharmaceuticals USA, Inc.Uzedy | $33 | $20,30111 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $271 | $19,92117 claims |
| MerckBelsomra | $3,692 | $8,31621 claims |
| Lilly USA, LLCOlanzapine | $123 | $1,47076 claims |
| Almatica Pharma LLCSertraline Hcl | $24 | $14113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 680 psychiatry providers in Missouri.
Other psychiatry in Saint Louis
- Junaid SyedSaint Louis$8M
- Ricky MofsenSaint Louis$4.9M
- Charles ConwaySaint Louis$3.8M
- Mohd MalikSaint Louis$2.8M
- Vadim BaramSaint Louis$1.9M
- Adam SkySaint Louis$1.1M
- Mary KimmelSaint Louis$539K
- George GrossbergSaint Louis$521K
- Asif HabibSaint Louis$517K
- Eric LenzeSaint Louis$271K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.